Patent strengthens 3D Ready(TM) portfolio, enabling consistent, assay-ready organoids for predictive drug discovery SAN JOSE, Calif., Nov. 13, 2025 /PRNewswire-PRWeb/ -- Molecular Devices, LLC., a ...
Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to ...
You don't want to miss this! To permanently access this eBook for free, fill out the short form below. Researchers are under pressure to scale complex cell culture models—like iPSCs and 3D ...
I reiterate my 'Strong Buy' rating for Danaher, with a one-year price target of $310 per share, citing recovery in bioprocessing and market share gains in molecular testing. Danaher's bioprocessing ...
BOULDER, Colo. , Jan. 7, 2025 /PRNewswire/ -- Danaher Cryogenics, a leader in manufacturing of fully-integrated, sub-Kelvin cryostats and engineering elegant cryogenic solutions, today announced the ...
With us today are Rainer Blair, our President and Chief Executive Officer; and Matt McGrew, our Executive Vice President and ...
We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback